Note: in alphabetical order by surname
MetInfo enterprise content manager system | MetInfo CMS

Cyber Cao

MetInfo enterprise content manager system | MetInfo CMS

Dandan Dong

MetInfo enterprise content manager system | MetInfo CMS

Shan Fu

Shan Fu has served as a director of VISEN since November 2018. Mr. Fu is a Managing Partner, Co-CEO and CEO of Greater China at Vivo Capital, a healthcare focused investment firm formed in 1996. Before joining Vivo in 2013, Mr. Fu worked for Blackstone as Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone’s Beijing Office. Mr. Fu also worked in the Department of Foreign Investment in China’s National Development and Reform Commission (NDRC), the State Economic and Trade Commission of China, the Office of Economic and Trade in State Council of China, and the Office of Production in State Council of China.

Mr. Fu received a Bachelor’s and Master’s Degree in History from Peking University in Beijing, China.

Dandan Dong, Ph.D., is a Managing Director of Vivo Capital with a background in academic biomedical science research and translational medicine. Dr. Dong is the founding team member of VISEN Pharmaceuticals and currently serves as VISEN’s Chief Business Officer. She has more than nine years’ experience in healthcare investments in both the United States and China. She has been involved in multiple transactions in both countries and cross-border deals. She is a managing member of Vivo PANDA Fund, Vivo’s early-stage investment vehicle.

She has conducted research in infectious disease and immunology and published her research in multiple peer-reviewed journals, including Infection and Immunity, the Journal of Infectious Disease etc. Dr. Dong holds a Ph.D. in biomedical science from Fudan University and she has completed the Pre-doctoral Fellowship program at New York University School of Medicine.

Managing Director,Sequoia Capital China. Prior to joining Sequoia, Cyber participated multiple investments Vivo Capital made in China. Before that, Cyber was the leader of Nycomed North Asia strategy and business development, and He helped Nycomed refurbish its China business and played an integral role in its acquisition of Techpool, a leading Chinese pharmaceutical player. In his early career, Cyber was at McKinsey & Company where he worked with both multi-national and local pharmaceutical companies on corporate strategy. Cyber received his M.S. in Pharmacy Administration and a B.S. in Pharmaceutics from Peking University.

MetInfo enterprise content manager system | MetInfo CMS

Michael Wolff Jensen

MetInfo enterprise content manager system | MetInfo CMS

Pony Lu

MetInfo enterprise content manager system | MetInfo CMS

Jan Møller Mikkelsen

With 28 years working experience in pharmaceutical market, Pony currently serves as CEO in VISEN Pharmaceuticals, a joint venture majorly shared by Ascendis Pharma and VIVO Capital. Pony has rich experience in Greater China (including HK and Taiwan) and Europe. He formerly served in Takeda for 7 years as the China President and Area Head of Greater China. Before that, he has spent 16 years at Servier Taiwan,China and France. His earlier career was with Astra-Zeneca Taiwan.

Pony was with Takeda through its critical growth phase. Under his leadership, Takeda China has reached sales revenue increase more than 10 times. As a challenge to himself, Pony has chosen to build VISEN from scratch and make it into a successful Biotech company, an emerging expert of endocrine-related disease therapy.

Michael Wolff Jensen has served as Chairman of Ascendis Pharma board of directors since January 2008 and as Senior Vice President, Chief Legal Officer since June 2013. and as Senior Vice President, Chief Legal Officer since June 2013. In addition, Mr. Jensen served as Acting Chief Financial Officer from May 2008 to June 2013. From October 2010 to June 2013, Mr. Jensen served as Senior Legal Advisor and Head of Partnerships (France) for the renewable business division of Dong Energy A/S, the Danish State-owned utility company. Prior to Ascendis Pharma, Mr. Jensen served as Executive Vice President & Chief Financial Officer of LifeCycle Pharma A/S, now known as Veloxis Pharmaceuticals A/S, a publicly traded biotechnology company, from 2003 to 2008. Prior to joining Veloxis, Mr. Jensen served as Senior Vice President & Chief Financial Officer of Genmab A/S, a publicly traded biotechnology company from 2000 to 2003. Mr. Jensen also currently serves as Chairman of the board of directors of XSpray Pharma AB; a publicly traded biotechnology company.

Mr. Jensen received an L.L.M. degree from the University of Copenhagen.

Jan Møller Mikkelsen has served as a director of VISEN since November 2018. Mr. Mikkelsen founded Ascendis Pharma and has served as President and Chief Executive Officer as well as Board member since December 2007. From 2002 to 2006, Mr. Mikkelsen was President and Chief Executive Officer of LifeCycle Pharma A/S, now traded under the name Veloxis Pharmaceuticals A/S. From 2000 to 2002, Mr. Mikkelsen was President of the Pharmaceutical Division of Maxygen, Inc.. Prior to that, Mr. Mikkelsen co-founded ProFound Pharma A/S, a biopharmaceutical company acquired by Maxygen, Inc., and at ProFound, he served as Co-Chief Executive Officer from 1999 to 2000. From 1988 to 1999, Mr. Mikkelsen held various positions at Novo Nordisk A/S, a global healthcare company, including Vice President of Protein Discovery. Mr. Mikkelsen currently serves on the advisory board of Inspirion Delivery Technologies, a specialty pharmaceutical company.

Mr. Mikkelsen received a Cand. Scient. degree in Biochemistry from the University of Odense, Denmark, and pursued his post-doctoral research at Children’s Hospital in Oakland, CA.

MetInfo enterprise content manager system | MetInfo CMS

Cyber Cao

Managing Director,Sequoia Capital China. Prior to joining Sequoia, Cyber participated multiple investments Vivo Capital made in China. Before that, Cyber was the leader of Nycomed North Asia strategy and business development, and He helped Nycomed refurbish its China business and played an integral role in its acquisition of Techpool, a leading Chinese pharmaceutical player. In his early career, Cyber was at McKinsey & Company where he worked with both multi-national and local pharmaceutical companies on corporate strategy. Cyber received his M.S. in Pharmacy Administration and a B.S. in Pharmaceutics from Peking University.

MetInfo enterprise content manager system | MetInfo CMS

Dandan Dong

Dandan Dong, Ph.D., is a Managing Director of Vivo Capital with a background in academic biomedical science research and translational medicine. Dr. Dong is the founding team member of VISEN Pharmaceuticals and currently serves as VISEN’s Chief Business Officer. She has more than nine years’ experience in healthcare investments in both the United States and China. She has been involved in multiple transactions in both countries and cross-border deals. She is a managing member of Vivo PANDA Fund, Vivo’s early-stage investment vehicle.

She has conducted research in infectious disease and immunology and published her research in multiple peer-reviewed journals, including Infection and Immunity, the Journal of Infectious Disease etc. Dr. Dong holds a Ph.D. in biomedical science from Fudan University and she has completed the Pre-doctoral Fellowship program at New York University School of Medicine.

MetInfo enterprise content manager system | MetInfo CMS

Shan Fu

Shan Fu has served as a director of VISEN since November 2018. Mr. Fu is a Managing Partner, Co-CEO and CEO of Greater China at Vivo Capital, a healthcare focused investment firm formed in 1996. Before joining Vivo in 2013, Mr. Fu worked for Blackstone as Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone’s Beijing Office. Mr. Fu also worked in the Department of Foreign Investment in China’s National Development and Reform Commission (NDRC), the State Economic and Trade Commission of China, the Office of Economic and Trade in State Council of China, and the Office of Production in State Council of China.

Mr. Fu received a Bachelor’s and Master’s Degree in History from Peking University in Beijing, China.

MetInfo enterprise content manager system | MetInfo CMS

Michael Wolff Jensen

Michael Wolff Jensen has served as Chairman of Ascendis Pharma board of directors since January 2008 and as Senior Vice President, Chief Legal Officer since June 2013. and as Senior Vice President, Chief Legal Officer since June 2013. In addition, Mr. Jensen served as Acting Chief Financial Officer from May 2008 to June 2013. From October 2010 to June 2013, Mr. Jensen served as Senior Legal Advisor and Head of Partnerships (France) for the renewable business division of Dong Energy A/S, the Danish State-owned utility company. Prior to Ascendis Pharma, Mr. Jensen served as Executive Vice President & Chief Financial Officer of LifeCycle Pharma A/S, now known as Veloxis Pharmaceuticals A/S, a publicly traded biotechnology company, from 2003 to 2008. Prior to joining Veloxis, Mr. Jensen served as Senior Vice President & Chief Financial Officer of Genmab A/S, a publicly traded biotechnology company from 2000 to 2003. Mr. Jensen also currently serves as Chairman of the board of directors of XSpray Pharma AB; a publicly traded biotechnology company.

Mr. Jensen received an L.L.M. degree from the University of Copenhagen.

MetInfo enterprise content manager system | MetInfo CMS

Pony LU

With 28 years working experience in pharmaceutical market, Pony currently serves as CEO in VISEN Pharmaceuticals, a joint venture majorly shared by Ascendis Pharma and VIVO Capital. Pony has rich experience in Greater China (including HK and Taiwan) and Europe. He formerly served in Takeda for 7 years as the China President and Area Head of Greater China. Before that, he has spent 16 years at Servier Taiwan,China and France. His earlier career was with Astra-Zeneca Taiwan.

Pony was with Takeda through its critical growth phase. Under his leadership, Takeda China has reached sales revenue increase more than 10 times. As a challenge to himself, Pony has chosen to build VISEN from scratch and make it into a successful Biotech company, an emerging expert of endocrine-related disease therapy.

MetInfo enterprise content manager system | MetInfo CMS

Jan Møller Mikkelsen

Jan Møller Mikkelsen has served as a director of VISEN since November 2018. Mr. Mikkelsen founded Ascendis Pharma and has served as President and Chief Executive Officer as well as Board member since December 2007. From 2002 to 2006, Mr. Mikkelsen was President and Chief Executive Officer of LifeCycle Pharma A/S, now traded under the name Veloxis Pharmaceuticals A/S. From 2000 to 2002, Mr. Mikkelsen was President of the Pharmaceutical Division of Maxygen, Inc.. Prior to that, Mr. Mikkelsen co-founded ProFound Pharma A/S, a biopharmaceutical company acquired by Maxygen, Inc., and at ProFound, he served as Co-Chief Executive Officer from 1999 to 2000. From 1988 to 1999, Mr. Mikkelsen held various positions at Novo Nordisk A/S, a global healthcare company, including Vice President of Protein Discovery. Mr. Mikkelsen currently serves on the advisory board of Inspirion Delivery Technologies, a specialty pharmaceutical company.

Mr. Mikkelsen received a Cand. Scient. degree in Biochemistry from the University of Odense, Denmark, and pursued his post-doctoral research at Children’s Hospital in Oakland, CA.